SCHEMBL667525

SCHEMBL667525

COc1cccc(CN2CCC3(CC2)OCCO3)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.63
KDM4E B2RXH2 3/20 0.60
ALDH1A1 P00352 3/20 0.60
HTR1A P08908 1/20 0.56
DRD2 P14416 1/20 0.56
HTR2B P41595 1/20 0.56
GAA P10253 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MMP1 P03956 1/20 0.50
MMP9 P14780 1/20 0.50
MMP13 P45452 1/20 0.50
ADAM17 P78536 1/20 0.50
MAPT P10636 1/20 0.50
TSHR P16473 1/20 0.50
LMNA P02545 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KCNH2 Q12809 1/20 0.50
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12625929 0.83 SIGMAR1 (0.59) SIGMAR1KDM4EALDH1A1HTR1ADRD2
SCHEMBL20804357 0.82 SIGMAR1 (0.90) SIGMAR1KDM4EALDH1A1HTR1ADRD2
SCHEMBL28186295 0.82 SIGMAR1 (0.90) SIGMAR1KDM4EALDH1A1HTR1ADRD2
SCHEMBL13791587 0.81 SIGMAR1 (0.72) SIGMAR1KDM4EALDH1A1HTR1ADRD2
SCHEMBL12625928 0.81 SIGMAR1 (0.56) SIGMAR1KDM4EALDH1A1HTR1ADRD2
SCHEMBL3162705 0.79 SIGMAR1 (0.79) SIGMAR1KDM4EALDH1A1HTR1ADRD2
SCHEMBL30774908 0.79 SIGMAR1 (0.79) SIGMAR1KDM4EALDH1A1HTR1ADRD2
SCHEMBL9572753 0.79 ALDH1A1 (0.60) SIGMAR1KDM4EALDH1A1GAASMN1; SMN2
SCHEMBL1883482 0.78 SIGMAR1 (0.77) SIGMAR1KDM4EALDH1A1GAASMN1; SMN2
SCHEMBL29447356 0.78 SIGMAR1 (0.77) SIGMAR1KDM4EALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045468-B2 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-06-02 US disclosed
EP-2606049-A2 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN Albany Molecular Research, Inc. (US) 2013-06-26 EP disclosed
US-20120046271-A1 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-23 US disclosed
WO-2012024397-A2 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2012-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046271-A1 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin HTR2B, HTR1B, HTR5A SIGMAR1 97/4885KDM4E 1605/4885ALDH1A1 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.